Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 604 trials

Advanced Gastric Cancer: [18F]AlF-FAPI-74 PET/CT Study

We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.

Advanced Gastric CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal MedicineOncology

RSV Vaccination in Stem Cell Transplant Recipients

We are studying two RSV vaccines to see how well they work in patients who have received stem cell transplants. The goal is to understand their immune response and effectiveness compared to healthy individuals.

Allogeneic Hematopoietic Stem Cell Transplantation≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesInternal Medicine

Type 1 Diabetes: Diamyd Study

We are investigating whether the drug Diamyd can help preserve insulin production in adolescents and adults recently diagnosed with type 1 diabetes. The study will also look at the safety of Diamyd compared to a placebo.

Type 1 Diabetes>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

Urethral Stenosis: Innovative Fat Injection Treatment

We are studying the safety and potential benefits of injecting fat-derived cells for men with recurrent urethral stenosis after surgery. This trial aims to see if this treatment can improve symptoms and reduce the need for further procedures.

Urethral Stenosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesUrology

Type 1 Diabetes: Diamyd® Treatment Study

We are evaluating the safety and feasibility of Diamyd® injections in young people at risk for Type 1 diabetes. This study looks at how the treatment affects their immune system and progression of the disease.

Type 1 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Telmisartan for Portal Hypertension in Liver Disease

We are studying whether telmisartan can lower liver pressure in patients with advanced chronic liver disease and portal hypertension. This trial will also assess its safety and impact on quality of life.

Compensated Advanced Chronic Liver DiseasePortal Hypertension3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteHepatologyInternal Medicine

Dupilumab for Uncontrolled Moderate to Severe Asthma

We are studying whether dupilumab can help prevent lung function decline in adults with uncontrolled moderate to severe asthma. This trial will compare its effects to a placebo over time.

AsthmaMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementAllergologyPulmonology

CSL889 for Sickle Cell Disease: A New Treatment

We are studying the safety and effects of CSL889 in adults and adolescents with sickle cell disease during painful vaso-occlusive crises. The goal is to see if it helps speed up recovery compared to a placebo.

Sickle Cell Anemia with Crisis≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Kidney Transplantation: Donor Modified Immune Cells

We are studying whether using specially modified immune cells can help patients tolerate their new kidney better than standard treatments. The trial also looks at the safety of this new approach in preventing infections and other complications.

Kidney Transplant>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Polymyalgia Rheumatica: Rituximab Study

We are investigating whether rituximab can help reduce the need for corticosteroids in people with relapsing polymyalgia rheumatica. This study compares rituximab to a placebo to assess its effectiveness.

Polymyalgia Rheumatica1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyRheumatology

YTB323 for Treatment-Resistant Generalized Myasthenia Gravis

We are studying the safety and effects of YTB323 in patients with treatment-resistant generalized myasthenia gravis. This research aims to understand how the drug works in the body and its potential to improve symptoms.

Myasthenia Gravis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Stroke Prevention: Low Dose Colchicine Study

We are investigating whether low dose colchicine can help prevent future strokes and other major vascular events in patients with a history of stroke due to atherosclerosis.

Cardiovascular Diseases>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Obesity: PF-07976016 Medication Study

We are testing a new medication called PF-07976016 to see if it helps adults with obesity lose weight more effectively than a placebo. The study also looks at the safety of this medication for those already taking liraglutide.

ObesityOverweight6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteDiabetologyEndocrinology

Idiopathic Inflammatory Myopathies: Upadacitinib Study

We are testing whether Upadacitinib can help patients with idiopathic inflammatory myopathies maintain stable disease after stopping IVIG treatment. The study compares its effects to a placebo over 16 weeks.

PolymyositisDermatomyositisAntisynthetase Syndrome3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesDermatologyRheumatology

Osteoarthritis Behind the Kneecap: Nasal Cartilage Implantation

We are studying a new nasal cartilage treatment for people with osteoarthritis behind the kneecap to see if it improves recovery compared to standard care. The trial will also assess safety and how well the treatment works over time.

Knee OsteoarthritisPatellofemoral Osteoarthritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Triple-Negative Breast Cancer: Ceralasertib with Durvalumab and Nab-Paclitaxel

We are studying a new treatment approach for patients with advanced triple-negative breast cancer who have relapsed after prior therapies. This trial aims to see if combining ceralasertib with other medications can improve their response to treatment.

Advanced Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Intrahepatic Cholangiocarcinoma: PUMP IV Trial

We are studying a new chemotherapy method to help prevent liver cancer from coming back after surgery. This trial will also look at side effects and how it affects patients' quality of life.

Intrahepatic Cholangiocarcinoma3-6 monthsEfficacy phase (II)6-10 visitsCost ReimbursementGastroenterologyHepatologyOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Rare Cancers: Targeted Drug Study

We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.

Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Acute Myocarditis: Ibuprofen vs. Standard Pain Relief

We are studying whether ibuprofen can better improve heart health compared to regular pain relief in patients with acute myocarditis. This trial focuses on how these treatments affect heart imaging results after six months.

Acute Myocarditis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine